Latest Tax Incentives News

Avecho Biotechnology has secured a unanimous recommendation to continue its Phase III insomnia trial without increasing sample size, alongside raising $1.9 million through option exercises and bolstering its cash position to $6.6 million.

Centaurus Metals has made significant strides towards a Final Investment Decision for its Jaguar Nickel Sulphide Project, securing strong debt financing interest, critical infrastructure approvals, and advancing engineering and pre-development works in Brazil.

Sea Forest Limited accelerated its commercial momentum in 4Q26 with an 83% revenue increase to $2.1 million, underpinned by new cattle supply agreements and the commissioning of its first regional distribution centre in Newcastle.

Carnegie Clean Energy has made substantial progress on its ACHIEVE Programme, including module assembly and regulatory approvals for ocean deployment in Spain, supported by a $2.5 million private placement to fund commercial expansion.

Talius Group maintained steady revenue in Q2 2026, boosted by $2 million in new aged care contracts and a 10% increase in active subscriptions.

Clean TeQ Water has marked a milestone with its inaugural recurring revenue from ATA® technology and a 45% jump in quarterly customer receipts, underpinned by contract wins and project progress across global water and critical minerals markets.

Proteomics International Laboratories has streamlined operations, secured a key US patent for its endometriosis test, and inked a three-year exclusive distribution deal with Healius for its Promarker diagnostics in Australia.

Yojee has transitioned its MOSAIC freight forwarding platform into commercial operations, securing multiple contracts including two long-term Everest Founding Partners and outlining a strategic AI-driven roadmap.

Energy Action Limited's unaudited FY26 results show a sharp profit decline to $0.45 million on stable revenue of $12.2 million, weighed down by lower R&D incentives and higher costs.

Argenica Therapeutics is gearing up for a pivotal late-stage clinical trial of its neuroprotective drug ARG-007 (xaranetide) in acute ischaemic stroke, backed by strong safety assays and solid funding.

Spenda Limited anticipates a significant R&D tax offset exceeding AUD 1.75 million for FY26, providing a timely cash boost amid its push towards cash-flow neutrality.

PainChek has received a $1.123 million R&D tax incentive refund for FY2025, reinforcing its cash reserves and underpinning ongoing development of AI pain assessment algorithms and US market validation.